Core Viewpoint - The "2025 Health China Innovation Practice Case Collection and Display Activity" has been officially launched to promote innovative practices and advanced experiences in health management and patriotic health movements across various regions and units [1] Group 1: Collection Details - The collection is open to the entire society, including government bodies, public hospitals, schools, research institutions, social organizations, and enterprises [2] - The collection period is from now until September 20, 2025 [3] Group 2: Collection Content - Cases related to health weight management, focusing on innovative management measures and typical experiences in implementing weight management systems [3] - Cases related to medical foundation projects, emphasizing innovations in rural health construction, county medical capacity enhancement, and community health services [3] - Cases in health digitalization and technology transfer, including applications of AI in diagnosis, digital hospital construction, and telemedicine services [3] - Cases in traditional Chinese medicine health initiatives, focusing on cultural literacy, service improvements, and non-drug therapies [4] Group 3: Case Requirements - The submitted cases must be based on real examples, avoiding fabrication or exaggeration [5] - Cases should be typical and provide meaningful solutions that can serve as references for other regions [6] - Submissions must include background, specific measures, and results, supported by data or charts [6] - The logic, methods, and technical solutions in the cases must adhere to scientific principles and comply with policies and ethics [6] Group 4: Submission Method - Cases should be submitted via email, with a specific subject format and additional materials allowed [8] - Contact information for inquiries is provided, including names and phone numbers [8] Group 5: Application of Case Results - Selected cases will be showcased on the People's Health platform [9] - Invited units will participate in case research and exchange to promote results [9] - Eligible cases may become partners in the People's Daily data intelligence program for deeper collaboration [9]

Core Viewpoint - The article highlights the advancements in the diagnosis and treatment of brain gliomas, particularly focusing on the innovative Raman optical biopsy technology developed by Jiangsu Raman Medical Equipment Co., Ltd. This technology aims to improve the accuracy and speed of glioma diagnosis, addressing the limitations of traditional methods [2][4][14]. Group 1: Research Background - Brain gliomas account for 26.5% of central nervous system tumors, with glioblastoma (GBM) representing 46.1% of gliomas. The annual incidence rate is approximately 3.2-6.4 per 100,000 people [2]. - The median overall survival (mOS) for glioblastoma patients is only 14.6-20.9 months, with a 5-year survival rate below 3-5% [2]. - MRI is the primary diagnostic tool, but it struggles to accurately differentiate tumor subtypes and boundaries. Traditional pathological diagnosis is time-consuming and cannot meet intraoperative needs [2]. Group 2: Product Introduction - Jiangsu Raman Medical Equipment Co., Ltd. has developed a brain glioma pathological tissue analysis instrument, which utilizes Raman resonance scattering principles to detect specific chemical components and concentrations in biological tissues [3][4]. - The instrument offers real-time, rapid detection in just 1 second, providing higher accuracy at the molecular level and enabling non-invasive, intraoperative diagnostics [4]. Group 3: Market Overview - The global tissue pathology diagnostic equipment market is projected to reach $3.344 billion in 2024, growing to $5.326 billion by 2031, with a CAGR of 6.4% [9]. - The AI-assisted disease imaging analysis market is expected to reach $32.7 billion by 2025, with a CAGR of 28.4%, and China is anticipated to have the fastest growth rate, exceeding 35% [9]. - The Chinese market for tissue pathology diagnostic equipment is rapidly evolving, with significant growth expected through 2031, outpacing global averages [9]. Group 4: Competitor Analysis - Nico Corporation (USA) has developed the BrainPath system, which integrates intraoperative imaging and navigation for glioma surgery, though it comes with a high cost [10]. - European companies like Horiba and Renishaw offer Raman spectroscopy systems widely used in research and clinical trials, but these are primarily laboratory devices requiring further optimization for clinical application [10]. Group 5: Technological Advancements - A clinical trial at Beijing Tiantan Hospital is exploring new diagnostic techniques using optical electronic ex vivo brain tumor analysis instruments alongside traditional pathological examinations [5]. - Jiangsu Raman Medical Equipment Co., Ltd. has contributed to research presented at the SPIE BIOS conference, focusing on the use of portable Raman analyzers for brain tumor detection [6].

Core Viewpoint - The medical technology industry is at a crossroads of breakthrough and reconstruction, with advancements in AI-assisted diagnosis, high-end smart medical devices, innovative medical materials, and regenerative medicine reshaping disease discovery, treatment, and management [1]. Group 1: Conference Overview - The Second Global MedTech Conference will be held on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, aiming to promote the collaborative development of the global medical technology industry chain, innovation chain, and clinical applications [1][4]. - The first conference, Global MedTech Conference 2024, was organized by Siyu [2]. Group 2: Awards and Recognition - The conference will present several awards to recognize breakthroughs in medical technology, including the 2025 Global MedTech Innovation Award and the 2025 Global MedTech Clinical Application Award [3][7]. - The awards aim to honor cutting-edge technological advancements, successful results transformation, and outstanding services in the medical technology field [3]. Group 3: Conference Agenda - Proposed agenda topics include analysis of global medical technology development trends and policy environments, research and transformation paths for imaging platforms, new consumables, brain-computer interfaces, interventional devices, and diagnostic equipment [5]. - Other topics will cover the intersection of engineering and medicine, AI-assisted diagnosis, digital therapy breakthroughs, and capital market interests in technology directions and company profiles [5]. Group 4: Participation and Submission Guidelines - The awards are open to medical device and digital medical technology companies with innovative products or platform technologies that demonstrate originality, advancement, and scalability potential [6]. - Submission for the awards is open until May 31, 2025, with a review phase from June 1 to June 15, 2025, and results to be announced between June 16 and June 22, 2025 [10].

Core Viewpoint - CapsoVision is planning an IPO to raise up to $30 million to enhance its position in the non-invasive gastrointestinal diagnostics market, particularly for its CapsoCam Plus product [1]. Company Overview - CapsoVision, founded in 2006 and headquartered in Saratoga, California, focuses on non-invasive gastrointestinal diagnostic technologies and has entered multiple markets including North America, Europe, and Asia-Pacific [14]. Product Introduction - The core product, CapsoCam Plus, is a swallowable capsule endoscope designed for small intestine examinations, providing non-invasive and high-quality imaging [2]. - The product received FDA 510(k) certification in 2016 and expanded its indications to include pediatric patients aged 2 and above in 2025 [2]. Product Features - CapsoCam Plus features 360° panoramic imaging with four side cameras, significantly improving visual coverage compared to traditional forward-facing lenses [3]. - It offers wireless data storage, eliminating the need for external receiving devices, and allows for natural expulsion through bowel movements [3]. - The high-resolution images support the identification of common small intestine lesions such as ulcers and bleeding [3]. - The examination process does not require anesthesia or hospitalization, making it suitable for patients who are reluctant to undergo traditional endoscopy, especially children and the elderly [3]. Market Demand - The incidence of gastrointestinal diseases is rising globally, with approximately 20 million new cancer cases reported in 2023, including colorectal and gastric cancers [8]. - The global capsule endoscopy market was valued at approximately $537 million in 2023 and is projected to grow to between $1.02 billion and $1.6 billion by 2030, with a CAGR of 8.4%-9.6% [8]. - The Asia-Pacific region, particularly China, is the fastest-growing market, expected to achieve over 15% CAGR by 2030, with a market size potentially exceeding 3 billion RMB [8]. Competitive Landscape - The capsule endoscopy market is highly concentrated, with Medtronic leading globally, while local companies like AnHuan and Jinshan are rapidly emerging in the Chinese market [9][11]. - CapsoVision's CapsoCam Plus competes with products from Medtronic, IntroMedic, and Olympus, each offering unique features such as AI integration and remote access capabilities [9][11]. Software and Technology - The CapsoView software, launched in 2023, supports cloud-based access and data sharing, enhancing image analysis efficiency [7][10]. - The company is exploring the integration of artificial intelligence to improve diagnostic accuracy and efficiency [7][10].

2025年4月10日，国家药品监督管理局（NMPA）公布，鹰瞳科技旗下的 Airdoc-AIFUNDUS 2.0眼底 病变眼底图像辅助诊断软件 通过三类医疗器械证审批，并在"第二十五届国际眼科学学术会议"与"第二十 五届国际视光学学术会议"（简称COOC 2025）上 首次亮相 ， 与配备万语大模型的鹰瞳Airdoc三大产 品线齐聚COOC 2025 ，共绘眼科和视光行业发展新蓝图。 # Airdoc-AIFUNDUS 2.0 眼底多病种AI诊断系统获NMPA认证 此次获批的 Airdoc-AIFUNDUS 2.0眼底病变眼底图像辅助诊断软件（简称Airdoc-AIFUNDUS 2.0） ， 在原有技术基础上取得新突破， 新增 视网膜静脉阻塞功能模块 。 这一获批标志着鹰瞳Airdoc在人工智能辅助诊断领域的技术实力和创新能力再度获得国家权威机构认可， 同时进一步强化了鹰瞳Airdoc在视网膜影像AI多病种诊断领域的领先地位。 | 2022年11月1日起,行政相对人可登录国家药品监督管理局政务服务门户的法人空间查看电子证照,按照相关提示自行打印 | | --- | | 序 号 | 受理号 | 产品名称 | 申 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 名额有限 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 2025年3月22日， 万东医疗 （600055.SH）发布了2024年年报。 # 财报数据 # 关于万东医疗 2024年营业收入 15.24亿 元，同比增长 23.26% ； 归母净利润1.57亿元，同比下降16.54%；扣非归 母净利润1.42亿元，同比增长4.84%；基本每股收益0.22元/股，同比下降16.73%。经营活动产生的现 金流量净额为2.18亿元，同比增长4.82%。 2024Q4营业收入 4.31亿 元，同比增长 38.73% ，环比增长9.74%； 归母净利润0.42亿元，同比下降 39.12%，环比增长34.29%；扣非归母净利润0.31亿元，同比增长1.36%，环比增长4.19%。 分产品：2024年 MRI销量为131套 、同比增长92.65%，收入同比增长75.24%； CT销量为317套 、 同比增长89.82%，收入同比增长55.27%； DSA销量为45套 、同比增长28.57%，收入同比增长 24.90%；DR销量为 ...